LUMOXITI
These highlights do not include all the information needed to use LUMOXITI safely and effectively. See full prescribing information for LUMOXITI.LUMOXITI (moxetumomab pasudotox-tdfk) for injection, for intravenous useInitial U.S. Approval: 2018
d6510282-1a57-4614-9859-299a227a089c
HUMAN PRESCRIPTION DRUG LABEL
Feb 8, 2022
AstraZeneca Pharmaceuticals LP
DUNS: 054743190
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
moxetumomab pasudotox
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (5)
IV Solution Stabilizer
Product Details
FDA regulatory identification and product classification information